US Stock MarketDetailed Quotes

RDY Dr. Reddy's Laboratories

Watchlist
  • 13.450
  • -0.260-1.90%
Close Mar 25 16:00 ET
11.21BMarket Cap17.89P/E (TTM)

About Dr. Reddy's Laboratories Company

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Company Profile

SymbolRDY
Company NameDr. Reddy's Laboratories
Listing DateApr 11, 2001
Issue Price10.04
Founded1984
CEOMr. Erez Israeli
MarketNYSE
Employees27048
Securities TypeDR
ADS Ratio1.0 : 5.0
Fiscal Year Ends03-31
AddressDoor No. 8-2-337,Road No. 3,Banjara Hills
CityHyderabad
ProvinceTelangana
CountryIndia
Zip Code500034
Phone91-40-49002900

Company Executives

  • Name
  • Position
  • Salary
  • Patrick Aghanian
  • Chief Executive Officer, European Generics
  • 63.09M
  • M. V. Ramana
  • Chief Executive Officer, Branded Markets, India and Emerging Countries
  • 82.74M
  • Marc Kikuchi
  • Chief Executive Officer, North America Generics
  • 53.48M
  • Erez Israeli
  • Chief Executive Officer
  • 197.09M
  • Phani Mitra B
  • Chief Information Officer
  • --
  • B Phanimitra
  • Chief Digital and Information Officer
  • 15.13M
  • M V Narasimham
  • Deputy Chief Financial Officer
  • 48.82M
  • Archana Bhaskar
  • Chief Human Resource Officer
  • 65.21M
  • Parag Agarwal
  • Chief Financial Officer
  • 64.66M
  • G.V. Prasad
  • Co-Chairman of the Board and Managing Director
  • 186.28M
  • K. Satish Reddy
  • Co-Chairman of the Board
  • 116.17M
  • Sanjiv Mehta
  • Independent Director
  • 3.32M
  • Dr. Alpna Seth, PhD
  • Independent Director
  • 8.25M
  • Leo Puri
  • Independent Director
  • 17.10M
  • Dr. K. P. Krishnan
  • Independent Director
  • 14.18M
  • Shikha Sanjaya Sharma
  • Independent Director
  • 13.34M
  • Kalpana Morparia
  • Independent Director
  • 1.67M
  • Dr. Claudio Albrecht
  • Independent Director
  • 16.09M
  • Penny Wan
  • Independent Director
  • 17.10M
  • Arun M. Kumar
  • Independent Director
  • 18.77M
  • Krishna Venkatesh
  • Global Head, Quality and Pharmacovigilance
  • 6.15M
  • Deepak Sapra
  • Global Head of Pharmaceutical Services and Active Ingredients
  • 41.90M
  • Sushrut Kulkarni
  • Global Head of Integrated Product Development Organisation
  • 55.63M
  • Sanjay Sharma
  • Global Head of Manufacturing
  • 66.05M
  • Dr. Jayanth Sridhar
  • Global Head of Biologics
  • 34.59M
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.